Infections are the second leading cause of non-cancer-related mortality in the first year of life after a patient is diagnosed with cancer. Vaccination is a key aspect of cancer care to reduce infection risk and the severity of infection-related complications, with the intent of enhancing cancer-related outcomes and quality of life. This article summarizes a GSK-sponsored industry theater, “Immunize to Optimize: Enhancing Cancer Care Through Vaccines”, held as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA, from May 30th–June 3rd 2025. The industry theater included presentations from three speakers from GSK in the USA: Leonard Friedland, Noha Eltoukhy, and Jean A. Hurteau. Friedland described how vaccination is crucial in reducing infection risk for patients with cancer, and that prioritizing vaccination strategy is key to comprehensive cancer care. Eltoukhy discussed the ASCO guideline for vaccination of adults with cancer, including key vaccinations recommended for this population and special considerations in adults with hematological cancer. Leading on from this, Friedland also considered ASCO’s key initiatives to improve
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً